JPWO2022038171A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022038171A5 JPWO2022038171A5 JP2023512107A JP2023512107A JPWO2022038171A5 JP WO2022038171 A5 JPWO2022038171 A5 JP WO2022038171A5 JP 2023512107 A JP2023512107 A JP 2023512107A JP 2023512107 A JP2023512107 A JP 2023512107A JP WO2022038171 A5 JPWO2022038171 A5 JP WO2022038171A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- disorder
- alkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 24
- 229910052805 deuterium Inorganic materials 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 10
- 210000003169 central nervous system Anatomy 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229940076279 serotonin Drugs 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004431 deuterium atom Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- AIUOUEPKBRDPLG-UHFFFAOYSA-N 1,3-benzoxathiole Chemical group C1=CC=C2SCOC2=C1 AIUOUEPKBRDPLG-UHFFFAOYSA-N 0.000 claims 2
- 208000012219 Autonomic Nervous System disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010065604 Suicidal behaviour Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 239000007916 tablet composition Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067303P | 2020-08-18 | 2020-08-18 | |
| US63/067,303 | 2020-08-18 | ||
| US202063131974P | 2020-12-30 | 2020-12-30 | |
| US63/131,974 | 2020-12-30 | ||
| PCT/EP2021/072898 WO2022038171A1 (en) | 2020-08-18 | 2021-08-18 | Phenethylamine derivatives, compositions, and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539113A JP2023539113A (ja) | 2023-09-13 |
| JPWO2022038171A5 true JPWO2022038171A5 (https=) | 2024-07-26 |
| JP2023539113A5 JP2023539113A5 (https=) | 2024-07-26 |
Family
ID=77564095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2023512107A Pending JP2023539113A (ja) | 2020-08-18 | 2021-08-18 | フェネチルアミン誘導体、組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12122741B2 (https=) |
| EP (2) | EP4200021A1 (https=) |
| JP (3) | JP7802769B2 (https=) |
| KR (3) | KR20230051486A (https=) |
| AU (2) | AU2021328671A1 (https=) |
| CA (2) | CA3186357A1 (https=) |
| WO (2) | WO2022038171A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| EP4405318A4 (en) * | 2021-09-25 | 2025-11-05 | Alexander Shulgin Res Institute Inc | PHENYLAKYLAMINES SUBSTITUTED |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| EP4594297A4 (en) * | 2022-09-26 | 2026-03-04 | Caamtech Inc | 2-(2-ETHOXY-4-(ETHYLTHIO)-5-METHOXYPHENYL)ETHAN-1-AMINIUM CHLORIDE |
| KR20250097837A (ko) * | 2022-10-28 | 2025-06-30 | 사이빈 아이알엘 리미티드 | 펜에틸아민 화합물, 조성물, 및 사용 방법 |
| EP4727538A2 (en) * | 2023-06-15 | 2026-04-22 | Tactogen Inc. | New formulations for mental disorders or mental enhancement |
| WO2025228547A1 (en) | 2024-05-01 | 2025-11-06 | Cybin Irl Limited | Processes for preparing phenethylamine compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| DE19859684A1 (de) * | 1998-12-23 | 2000-06-29 | Bayer Ag | Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2006079999A2 (en) | 2006-04-09 | 2006-08-03 | Barth Frederik H | Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| WO2008016677A2 (en) | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| CN104906669A (zh) | 2007-03-30 | 2015-09-16 | 菲利普莫里斯生产公司 | 用于输送药剂的装置和方法 |
| WO2016040822A1 (en) * | 2014-09-12 | 2016-03-17 | Pinpoint Testing, Llc | Ready-to-constitute analytical platforms for chemical analyses and quantification |
| PL3625228T3 (pl) * | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| CN112430187B (zh) | 2019-08-07 | 2023-01-17 | 北京奇点势能科技有限公司 | 一种α,β-氘代胺类化合物、氘代药物及其制备方法 |
| US11246860B2 (en) | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| JP2023544724A (ja) | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| WO2022182602A2 (en) | 2021-02-24 | 2022-09-01 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
| US20220323378A1 (en) | 2021-04-03 | 2022-10-13 | Shawn Joseph | Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity |
| WO2022221942A1 (en) | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prevention of drug diversion |
| WO2022225884A1 (en) | 2021-04-22 | 2022-10-27 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psychedelic compounds and uses thereof |
| BR112023025599A2 (pt) | 2021-06-08 | 2024-02-20 | Entheogenix Biosciences Inc | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. |
| WO2022271982A1 (en) | 2021-06-23 | 2022-12-29 | Synaptive Therapeutics, Llc | Substituted phenethylamine for treating inflammation and psychological disorders |
| WO2023283386A2 (en) | 2021-07-07 | 2023-01-12 | Arcadia Medicine, Inc. | Safer psychoactive compositions |
| CA3209813A1 (en) | 2021-07-14 | 2023-01-19 | Mydecine Innovations Group Inc. | Novel short-acting psychoactive compounds of the mdma class |
| CA3229713A1 (en) | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof |
| WO2023036473A1 (en) | 2021-09-08 | 2023-03-16 | Cybin Irl Limited | Combination drug therapies |
| EP4405318A4 (en) | 2021-09-25 | 2025-11-05 | Alexander Shulgin Res Institute Inc | PHENYLAKYLAMINES SUBSTITUTED |
| CA3244130A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | PHENETYLAMINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE |
| KR20240153566A (ko) | 2022-02-15 | 2024-10-23 | 사이빈 아이알엘 리미티드 | 치료적 펜에틸아민 조성물, 및 사용 방법 |
| AU2023242469A1 (en) | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| AU2023246690A1 (en) | 2022-03-31 | 2024-11-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| KR20250097837A (ko) | 2022-10-28 | 2025-06-30 | 사이빈 아이알엘 리미티드 | 펜에틸아민 화합물, 조성물, 및 사용 방법 |
-
2021
- 2021-08-18 US US18/041,731 patent/US12122741B2/en active Active
- 2021-08-18 AU AU2021328671A patent/AU2021328671A1/en active Pending
- 2021-08-18 EP EP21766581.9A patent/EP4200021A1/en active Pending
- 2021-08-18 CA CA3186357A patent/CA3186357A1/en active Pending
- 2021-08-18 EP EP21763068.0A patent/EP4200290A1/en active Pending
- 2021-08-18 KR KR1020237003815A patent/KR20230051486A/ko active Pending
- 2021-08-18 KR KR1020267007984A patent/KR20260044248A/ko active Pending
- 2021-08-18 WO PCT/EP2021/072898 patent/WO2022038171A1/en not_active Ceased
- 2021-08-18 AU AU2021327136A patent/AU2021327136B2/en active Active
- 2021-08-18 JP JP2023512063A patent/JP7802769B2/ja active Active
- 2021-08-18 KR KR1020237006128A patent/KR20230053611A/ko active Pending
- 2021-08-18 US US18/041,728 patent/US20240317704A1/en active Pending
- 2021-08-18 CA CA3186359A patent/CA3186359A1/en active Pending
- 2021-08-18 WO PCT/EP2021/072896 patent/WO2022038170A1/en not_active Ceased
- 2021-08-18 JP JP2023512107A patent/JP2023539113A/ja active Pending
-
2024
- 2024-09-05 US US18/825,122 patent/US20240425451A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185299A patent/JP2026041715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022038171A5 (https=) | ||
| JPWO2021234608A5 (https=) | ||
| JP6722200B2 (ja) | 複素環化合物の合成 | |
| JP2009534468A5 (https=) | ||
| JPWO2022038170A5 (https=) | ||
| JP2001510154A5 (https=) | ||
| JP2017508733A5 (https=) | ||
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| JP2010530403A5 (https=) | ||
| JP2019531279A5 (https=) | ||
| JP2010155827A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2007522135A5 (https=) | ||
| JP2011518857A5 (https=) | ||
| JPWO2021030555A5 (https=) | ||
| JP2008531558A5 (https=) | ||
| JP2010534669A5 (https=) | ||
| JP2011519845A5 (https=) | ||
| JPWO2023156453A5 (https=) | ||
| JPWO2021134086A5 (https=) | ||
| JPWO2023036473A5 (https=) | ||
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JPWO2022243285A5 (https=) | ||
| JP2011528030A5 (https=) |